Dr. Hobbs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
# STREET1
Boston, MA 02114Phone+1 617-724-1124
Summary
- I am a board certified hematologist and oncologist. I am the clinical director of the adult leukemia service at MGH. My clinical and research focus is the treatment of patients with leukemia, specifically patients with myeloproliferative neoplasms.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Icahn School of Medicine at Mount SinaiClass of 2008
Certifications & Licensure
ME State Medical License 2020 - 2026
RI State Medical License 2021 - 2026
MA State Medical License 2010 - 2025
NH State Medical License 2021 - 2025
FL State Medical License 2021 - 2023
NY State Medical License 2011 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Regorafenib in Patients With Advanced Myeloid Malignancies Start of enrollment: 2017 Apr 17
- PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Start of enrollment: 2017 Jun 14
- Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. Start of enrollment: 2018 Aug 28
- Join now to see all
Publications & Presentations
PubMed
- Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis.Rathnam K Venkat, Robert A Redd, Amyah C Harris, Martin J Aryee, Anna E Marneth
Blood Advances. 2024-12-10 - Pregnancy: MPN management before, during, and after pregnancy.Joan How, Gabriela Hobbs
Hematology. American Society of Hematology. Education Program. 2024-12-06 - Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable.Lisa Yuen, Tasos Gogakos, Leonardo Boiocchi, Gabriela Hobbs, Robert Hasserjian
American Journal of Hematology. 2024-11-22
Journal Articles
- Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid LeukemiaAreej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
Abstracts/Posters
- Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia VeraGabriela S. Hobbs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What Does the Future Look like for Myelofibrosis?November 6th, 2024- Asciminib Study Shows Sustained Improvement, Fewer Adverse EffectsMarch 27th, 2023
- Aussie Cancer Researcher Primed for 2023 with Groundbreaking Clinical Trial Data Releases ScheduledJanuary 16th, 2023
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
